Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Ivabradine (Primary)
- Indications Acute heart failure
- Focus Therapeutic Use
- Acronyms PRIME-HF
- 28 Feb 2020 This study is terminated (discontinued) as per results published in the American Heart Journal
- 28 Feb 2020 Primary endpoint Proportion of participants taking Ivabradine at 180 days has been met as per results published in the American Heart Journal
- 28 Feb 2020 Results published in the American Heart Journal